Department of Pathology, New York University School of Medicine, New York2Department of Radiation Oncology, New York University School of Medicine, New York.
Department of Radiation Oncology, New York University School of Medicine, New York.
JAMA Oncol. 2015 Dec;1(9):1325-32. doi: 10.1001/jamaoncol.2015.2756.
The recent success of cancer immunotherapy has demonstrated the power of the immune system to clear tumors, generating renewed enthusiasm for identifying ways to induce antitumor immune responses in patients. Natural antitumor immune responses are detectable in a fraction of patients across multiple malignant neoplasms and can be reactivated by targeting rate-limiting immunosuppressive mechanisms. In most patients, however, interventions to induce a de novo antitumor immune response are necessary. We review growing evidence that radiation therapy targeted to the tumor can convert it into an in situ tumor vaccine by inducing release of antigens during cancer cell death in association with proinflammatory signals that trigger the innate immune system to activate tumor-specific T cells. In addition, radiation's effects on the tumor microenvironment enhance infiltration of activated T cells and can overcome some of the barriers to tumor rejection. Thus, the complementary effects of radiation on priming and effector phases of antitumor immunity make it an appealing strategy to generate immunity against a patient's own individual tumor, that through immunological memory, can result in long-lasting systemic responses. Several anecdotal cases have demonstrated the efficacy of combining radiation with available immunotherapies, and results of prospective trials are forthcoming.
最近癌症免疫疗法的成功证明了免疫系统清除肿瘤的能力,这激发了人们寻找方法在患者中诱导抗肿瘤免疫反应的新热情。在多种恶性肿瘤的一部分患者中可以检测到天然抗肿瘤免疫反应,并且可以通过靶向限制免疫抑制机制来重新激活这些反应。然而,在大多数患者中,需要进行诱导新的抗肿瘤免疫反应的干预。我们回顾了越来越多的证据,表明针对肿瘤的放射治疗可以通过在癌细胞死亡时诱导抗原释放,同时引发引发先天免疫系统激活肿瘤特异性 T 细胞的促炎信号,将其转化为原位肿瘤疫苗。此外,放射治疗对肿瘤微环境的影响增强了活化 T 细胞的浸润,并可以克服肿瘤排斥的一些障碍。因此,放射治疗对抗肿瘤免疫的启动和效应阶段的互补作用使其成为一种有吸引力的策略,可以针对患者自身的个体肿瘤产生免疫,通过免疫记忆,可以产生持久的全身反应。一些偶然案例已经证明了将放射治疗与现有的免疫疗法相结合的疗效,并且即将公布前瞻性试验的结果。